Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s
Digest more
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The ...
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...
Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations ...
Analysts have recently revised their consensus price target for Novo Nordisk stock, reducing it from DKK 431.99 to DKK 400.24. This adjustment reflects both optimism about the company’s strategic ...
Partnership combines world-renowned pharmaceutical leadership with an agile health-tech platform to make the ...
AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) was approved in the U.S. for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback